Biocon has lashed out at Roche a day after the Swiss major secured an order from the Delhi High Court barring the Indian company from marketing its new drug, co-developed with Mylan, as a biosimilar of Swiss major’s blockbuster drug Herceptin, used for the treatment of HER-2 positive breast cancer.
“It is an extremely shocking, but not unexpected development. This proceeding is an attempt by Roche to protect their market monopoly and prevent Indian patients from accessing a more affordable trastuzumab,” Biocon said in a statement.
Canmab, to be sold by Biocon, and Hertraz, to be sold by Mylan were launched in India earlier this year as biosimilars to Roche’s trastuzumab, Herceptin, and positioned as affordable options to the drug and targetted at emerging markets. In anticipation of the launch of the new drugs, Roche had even slashed the price of its own drug by 50 per cent in India, while the products of Biocon and Mylan are priced at a 25 - 30 per cent discount to Herceptin’s new price.
On Friday, Roche claimed it had filed the case against Biocon, US-based Mylan and Drugs Controller General of India (DCGI) as it was its duty to ascertain if the drugs were indeed similar to its own innovation. Roche has alleged that the Clinical Trials Registry in India does not have any publicly available data on the Phase I and Phase II clinical trials carried out by the companies, a mandatory requirement, while developing the drug.
“There is very limited information in the public domain and we believe it is important to ensure that patients and physicians can make informed decisions. Furthermore, as far as we are aware, the Indian regulatory authorities have approved Biocon and Mylan Inc’s products as trastuzumab, as per their regulatory process, but it is unclear if the products meet the criteria for biosimilar products,” according to a spokesperson from Roche. Herceptin had earned Roche $6.4 billion in revenue across the globe last year, while clocking about $21 million in India.
Sources at the drug regulator's office said that companies are not required to conduct clinical trial phase I and II for generic version of drugs which are already available for sale in other markets, mainly in the innovator market, under the present law. "All norms and guidelines were followed while granting approval and details will be presented to the court. The company has also submitted all required data for ensuring clinical safety and efficacy of the drug," a senior official at the regulator's office said.
Another expert involved in the development of the drug said Phase I and Phase III of the trial process is mandatory while Phase II is optional. DCGI GN Singh refused to comment as the matter is subjudice.
However, Roche said, "in taking this action we are seeking to clarify if Biocon and Mylan Inc.’s products have demonstrated comparable efficacy and safety to our innovator product trastuzumab, and have been approved as biosimilar products.”
Meanwhile, Biocon maintained that “Canmab and Hertraz adhere to stringent quality standards and have been developed on the basis of applicable biosimilar guidelines.”
About 150,000 new patients are diagnosed with breast cancer every year in India, of which nearly a fourth of the cases are HER2-positive and eligible for treatment with Biocon and Mylan’s drug. The market is estimated at Rs 130 crore a year, and Biocon and Mylan expect to double this market by the end of 2014.
“Biocon and Mylan are committed to affordability & access and are driven by their purpose of expanding the pool of patients that can afford trastuzumab. We are confident that once we are heard by the court, this injunction placing certain limits on promotional activities will not stand,” the statement from Biocon said.
On Thursday, the Delhi High Court had placed an injuction on the sale of Canmab and Hertraz as the bio-similars of Roche's Herceptin or references to any data relating to Roche's Trastuzumab in any press releases, public announcements, promotional or other material.
Shares of Biocon Ltd closed at Rs 435.15 apiece, up about 3 per cent, Friday on the Bombay Stock Exchange.